About Macrocure
Macrocure is a company based in Petah Tikva (Israel) founded in 2008 was acquired by Leap Therapeutics in August 2016. Macrocure has raised $26 million across 3 funding rounds from investors including Leap Therapeutics, Pontifax Venture Capital and Viola Group. Macrocure operates in a competitive market with competitors including Celgene, Poseida Therapeutics, Juno Therapeutics, TScan Therapeutics and Sonoma Biotherapeutics, among others.
- Headquarter Petah Tikva, Israel
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$26 M (USD)
in 3 rounds
-
Latest Funding Round
$13 M (USD), Series B
Apr 27, 2011
-
Investors
Leap Therapeutics
& 3 more
-
Employee Count
Not available
-
Acquired by
Leap Therapeutics
(Aug 29, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Macrocure
Macrocure has successfully raised a total of $26M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $13 million completed in April 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Macrocure
Macrocure has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Leap Therapeutics, Pontifax Venture Capital and Viola Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Pontifax Venture Capital is focused on life sciences investments.
|
Locked | Locked | Locked | |
|
Investments are made in early-stage technology companies globally.
|
Locked | Locked | Locked | |
|
Investments are directed toward Israeli technology startups by Docor.
|
Locked | Locked | Locked |
Investor details for Macrocure
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Macrocure
Investment portfolio details for Macrocure
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Macrocure
Detailed financials for Macrocure
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Macrocure Comparisons
Peer comparison for Macrocure
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Macrocure
Macrocure operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Celgene, Poseida Therapeutics, Juno Therapeutics, TScan Therapeutics and Sonoma Biotherapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for cancer and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| Locked | Locked | Locked |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| Locked | Locked | Locked |
T-cell-based therapies for autoimmune and degenerative diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of immune cell therapies
|
Detailed competitors of Macrocure
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Macrocure
Complete news archive for Macrocure
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Macrocure
Macrocure was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Macrocure is headquartered in Petah Tikva, Israel. It is registered at Petah Tikva, Central District, Israel.
Nissim Mashiach is the current CEO of Macrocure.
Macrocure is a funded company, having raised a total of $26M across 3 funding rounds to date.
Macrocure was founded in 2008 in Petah Tikva, Israel, within the biotechnology sector. T-cell therapies are developed and commercialized by the company to address wound care needs. The proprietary CureXcell technology is utilized, involving activated white blood cells derived from healthy donor blood to support wound healing processes. Two pivotal Phase III clinical trials are ongoing for lower extremity chronic ulcers and chronic venous leg ulcers.
Macrocure's top competitors include Juno Therapeutics, Achilles Therapeutics and ArsenalBio.
Macrocure has 4 investors. Key investors include Leap Therapeutics, Pontifax Venture Capital, Viola Group, and Docor.